Sanofi Receivables 2010-2024 | SNY

Sanofi receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • Sanofi receivables for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Sanofi receivables for 2023 were $9.55B, a 3.03% increase from 2022.
  • Sanofi receivables for 2022 were $9.27B, a 4.22% decline from 2021.
  • Sanofi receivables for 2021 were $9.678B, a 13.1% increase from 2020.
Sanofi Annual Receivables
(Millions of US $)
2023 $9,550
2022 $9,270
2021 $9,678
2020 $8,557
2019 $8,889
2018 $8,574
2017 $8,156
2016 $8,090
2015 $8,201
2014 $9,503
2013 $9,074
2012 $9,655
2011 $11,201
2010 $8,641
2009 $8,389
Sanofi Quarterly Receivables
(Millions of US $)
2024-09-30
2024-06-30 $9,482
2024-03-31
2023-12-31 $9,550
2023-09-30
2023-06-30 $9,423
2023-03-31
2022-12-31 $9,270
2022-09-30
2022-06-30 $573
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $8,156
2017-09-30
2017-06-30 $7,544
2017-03-31
2016-12-31 $8,090
2016-09-30
2016-06-30 $8,235
2016-03-31
2015-09-30
2015-06-30 $8,590
2014-06-30 $9,791
2013-06-30 $9,943
2012-06-30 $10,530
2012-03-31
2011-12-31 $11,201
2011-09-30
2011-06-30 $11,092
2011-03-31
2010-12-31 $8,641
2010-09-30
2010-06-30 $8,915
2010-03-31
2009-12-31 $8,389
2009-09-30
2009-06-30 $7,994
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $130.241B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Innoviva (INVA) United States $1.263B 10.51